Newsroom

June 2019

• Featured News Jun 19, 2019

  World Sickle Cell Day 2019

  For over 40 years Novartis has been committed to understanding sickle cell disease and working towards treatment.

• Press release Jun 17, 2019

  New analysis of Novartis data confirms that Cosentyx® demonstrates durable comprehensive treatment across psoriatic disease

  For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx® as comprehensive treatment across multiple manifestations of…
• Press release Jun 14, 2019

  New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy

  Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[…
• Press release Jun 14, 2019

  Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001)

  Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many…
• Press release Jun 13, 2019

  Three quarters of people living with axial spondyloarthritis struggle to find a job, IMAS survey shows

  New European data from IMAS survey show that people living with axial spondyloarthritis (axSpA) suffer a delay in diagnosis of over 7 years, potentially leading to an increase in work-related…
• Press release Jun 12, 2019

  Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show

  Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg[1]  Data at 2 years demonstrate over 50% of adults with…
• Press release Jun 12, 2019

  Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis

  First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide[1…
• Ad hoc release Jun 07, 2019

  Novartis announces new leader of Pharmaceuticals Business Unit

  Marie-France Tschudin, an experienced Novartis leader, appointed to President, Novartis Pharmaceuticals Basel, June 7, 2019 - Novartis announced today that Marie-France Tschudin, currently…
• Ad hoc release Jun 07, 2019

  Novartis stellt neue Leiterin der Pharmaceuticals Business Unit vor

  Marie-France Tschudin, erfahrene Novartis Führungsperson, zur Präsidentin von Novartis Pharmaceuticals ernannt Basel, 7. Juni 2019 - Novartis kündigte heute an, dass Marie-France Tschudin,…
• Press release Jun 06, 2019

  Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare®

  Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare® for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium (177Lu)…
• Press release Jun 06, 2019

  Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible

  Data show 60% of iscalimab-treated transplant patients have normal kidney histology at least 1 year after transplant vs 0% with tacrolimus (current standard of care)[1] Less than half of donated…
• Press release Jun 04, 2019

  Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®

  Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine…